Brainstorm Cell Therapeutics Inc.

Good day, and welcome to the Brainstorm Cell Therapeutics first quarter 2020 conference call. At this time, all participants are in listen-only mode. As a reminder, this call is recorded, and I would now like to introduce your host for today's conference, Mr. Sean Leos from ICR Westwick. Mr. Leos, you may begin.

Thank you for joining the Brainstorm Cell Therapeutics call. Before we begin the opening remarks, We would like to remind listeners that this conference call contains numerous statements, descriptions, forecasts, and projections regarding Brainstorm Cell Therapeutics, NASDAQ, BCLI, and its potential future business operations and performance, statements regarding the market potential for the treatment of neurodegenerative disorders such as ALS and MS, the sufficiency of our existing capital resources for continuing operations in 2020 and beyond, the safety and clinical effectiveness of our Neuron technology platform, our clinical trials of Neuron and related clinical development programs, and our ability to develop strategic collaborations and partnerships to support our business planning efforts. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond our control. including the risks and uncertainties described from time to time in our SEC filings. Our results may differ in material from those projected here on today's call. We undertake no obligation to publicly update any forward-looking statements. Joining me on the call today will be Hein Leibowitz, CEO of Brainstorm, Dr. Ralph Kern, President and Chief Medical Officer, David Setboom, Chief Operating Officer, Freedom Shaw, Chief Financial Officer. They will be available to answer your questions during the Q&A session.

Thank you, Sean.